Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors or Lymphoma

Trial Profile

Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors or Lymphoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Nivolumab (Primary) ; Vinblastine (Primary)
  • Indications Glioma; Lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Metro-PD1
  • Most Recent Events

    • 18 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top